نتائج البحث - Silvia Bader‐Weder

  • يعرض 1 - 2 نتائج من 2
تنقيح النتائج
  1. 1
    An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy

    An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy حسب Jennifer M. Kwon, Kapil Arya, Nancy L. Kuntz, Han C. Phan, Cory Sieburg, Kathryn J. Swoboda, Aravindhan Veerapandiyan, Beverly Assman, Silvia Bader‐Weder, Travis L. Dickendesher, Jennifer L. Hansen, Helen Lin, Ying Yan, Vamshi K. Rao

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment

    Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment حسب Eugenio Mercuri, Giovanni Baranello, Odile Boespflug‐Tanguy, Liesbeth De Waele, Nathalie Goemans, Janbernd Kirschner, Riccardo Masson, Elena Mazzone, Astrid Pechmann, Maria Carmela Pera, Carole Vuillerot, Silvia Bader‐Weder, Marianne Gerber, Ksenija Gorni, Janine Hoffart, Heidemarie Kletzl, Carmen Martín, Tammy McIver, R. Scalco, Wai Yin Yeung, Laurent Servais

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: